Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia

John Weems, J.; P. Steinberg, James; G. Filler, Scott; W. Baddley, John; Ralph Corey, G.; Sampathkumar, Priya; G. Winston, Lisa; F. John, Joseph; J. Kubin, Christine; Talwani, Rohit; Moore, Thomas; M. Patti, Joseph; Hetherington, Seth; Texter, Michele; Wenzel, Eric; A. Kelley, Violet; G. Fowler, Vance

doi:10.1128/aac.00096-06

Public

Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia

Published in Antimicrobial Agents and Chemotherapy • Jul 26, 2006

Authors:

J. John Weems

James P. Steinberg

Scott G. Filler

Abstract

Tefibazumab (Aurexis), a humanized monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A, is under development as adjunctive therapy for serious Staphylococcus aureus infections. Sixty patients with documented S. aureus bacteremia (SAB) were randomized and receiv...

Subject

Medicine

Placebo

Bacteremia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!